Publications
Publications

Publications

  • 111. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
  • J. Fassunke, F. Müller, M. Keul, S. Michels, M.A. Dammert, A. Schmitt, D. Plenker, J. Lategahn, C. Heydt, J. Brägelmann, H.L. Tumbrink, Y. Alber, S. Klein, A. Heimsoeth, I. Dahmen, R.N. Fischer, M. Scheffler, M.A. Ihle, V. Priesner, A.H. Scheel, S. Wagener, A. Kron, K. Frank, K. Garbert, T. Persigehl, M. Püslek, S. Haneder, B. Schaaf, E. Rodermann, W. Engel-Riedel, E. Felip, E.F. Smit, S. Merkelbach-Bruse, H.C. Reinhardt, S.M. Kast, J. Wolf*, D. Rauh*, R. Büttner*, M.L. Sos*
  • Nature Communications20189(1)4655
  • 104. Donated chemical probes for open science.
  • S. Müller*, S. Ackloo, C.H. Arrowsmith, M. Bauser, J.L. Baryza, J. Blagg, J. Böttcher, C. Bountra, P.J. Brown, M.E. Bunnage, A.J. Carter, D. Damerell, V. Dötsch, D.H. Drewry, A.M. Edwards, J. Edwards, J.M. Elkins, C. Fischer, S.V.Frye, A. Gollner, C.E. Grimshaw, A. Ijzerman, T. Hanke, I.V. Hartung, S. Hitchcock, T. Howe, T.V. Hughes, S. Laufer, V.M. Li, S. Liras, B.D. Marsden, H. Matsui, J. Mathias, R.C. O’Hagan, D.R. Owen, V. Pande, D. Rauh, S.H. Rosenberg, B.L. Roth, N.S. Schneider, C. Scholten, K. Singh Saikatendu, A. Simeonov, M. Takizawa, C. Tse, P.R. Thompson, D.K. Treiber, A.Y. Viana, C.I. Wells, T.M. Willson, W.J. Zuercher, S. Knapp, A. Mueller-Fahrnow*
  • Elife201820;734311
  • 97. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.
  • J. Brägelmann, M.A. Dammert, F. Dietlein, J.M. Heuckmann, A. Choidas, S. Böhm, A. Richters, D. Basu, V. Tischler, C. Lorenz, P- Habenberger, Z. Fang, S. Ortiz-Cuaran, F. Leenders, J. Eickhoff, U. Koch, M. Getlik, M. Termathe, M. Sallouh, Z. Greff, Z. Varga, H. Balke-Want, C.A. French, M. Peifer, H.C. Reinhardt, L. Örfi, G. Kéri, S. Ansén, L.C. Heukamp, R. Büttner, D. Rauh, B.M. Klebl, R.K. Thomas, M.L. Sos*
  • Cell Rep201719(20)2833-45
  • 82. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
  • J. Engel, A. Richters, M. Getlik, S. Tomassi, M. Keul, M. Termathe, J. Lategahn, C. Becker, S. Mayer-Wrangowski, C. Grütter, N. Uhlenbrock, J. Krüll, N. Schaumann, S. Eppmann, P. Kibies, F. Hoffgaard, J. Heil, S. Menninger, S. Ortiz-Cuaran, J.M. Heuckmann, V. Tinnefeld, R.P. Zahedi, M.L. Sos, C. Schultz-Fademrecht, R.K. Thomas, S.M. Kast*, D. Rauh*
  • J Med Chem201558(17)6844-63
  • 81. Covalent-Allosteric Kinase Inhibitors.
  • J. Weisner, R. Gontla, L. van der Westhuizen, S. Oeck, J. Ketzer, P. Janning, A. Richters, T. Mühlenberg, Z. Fang, A. Taher, V. Jendrossek, S.C. Pelly, S. Bauer, W.A.L. van Otterlo, D. Rauh*
  • Angew Chem Int Ed Engl201554(35)10313-6
  • 78. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
  • F. Dietlein, B. Kalb, M. Jokic, E.M. Noll, A. Strong, L. Tharun, L. Ozretić, H. Künstlinger, K. Kambartel, W.J. Randerath, C. Jüngst, A. Schmitt, A. Torgovnick, A. Richters, D. Rauh, F. Siedek, T. Persigehl, C. Mauch, J. Bartkova, A. Bradley, M.R. Sprick, A. Trumpp, R. Rad, D. Saur, J. Bartek, J. Wolf, R. Büttner, R.K. Thomas, H.C. Reinhardt*
  • Cell2015162(1)146-59
  • 52. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
  • M. Peifer, L. Fernández-Cuesta, M.L. Sos, J. George, D. Seidel, L.H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen, C. Müller, D. Di Cerbo, H.U. Schildhaus, J. Altmüller, I. Baessmann, C. Becker, B. de Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J.M. Heuckmann, X. Lu, S.L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen I, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M. Brockmann, W. Engel-Riedel, L.A. Muscarella, V.M. Fazio, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D.A. Heideman, P.J. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O.T. Brustugun, M. Lund-Iversen, J. Sänger, J.H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J.C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P.M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Büttner, J. Wolf, P. Nürnberg, S. Perner, L.C. Heukamp, P.K. Brindle, S. Haas, R.K. Thomas*
  • Nat Genet201244(10)1104-10
  • 40. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
  • P.S. Hammerman, M.S. Sos, A.H. Ramos, C. Xu, A. Dutt, W. Zhou, L.E. Brace, B.A. Woods, W. Lin, J. Zhang, X. Deng, S.M. Lim, S. Heynck, M. Peifer, J.R. Simard, M.S. Lawrence, R.C. Onofrio, H.B. Salvesen, D. Seidel, T. Zander, J.M. Heuckmann, A. Soltermann, H. Moch, M. Koker, F. Leenders, F. Gabler, S. Querings, S. Ansén, E. Brambilla, C. Brambilla, P. Lorimier, O.T. Brustugun, A. Helland, I. Petersen, J.H. Clement, H. Groen, W. Timens, H. Sietsma, E. Stoelben, J. Wolf, D.G. Beer, M.S. Tsao, M. Hanna, C. Hatton, M.J. Eck, P.A. Jänne, B.E. Johnson, W. Winckler, H. Greulich, A.J. Bass, J. Cho, D. Rauh, N.S. Gray, K.K. Wong, E.B. Haura, R.K. Thomas* and M. Meyerson*
  • Cancer Discovery20111(1)78-89
  • 36. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer.
  • J. Weiss, M. Sos*, D. Seidel, M. Peifer, T. Zander, J. Heuckmann, R. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z.Wainer, M. Conron, G. Wright, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Solberg, O. T. Brustgun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner, R. Thomas*
  • Sci Transl Med20102(62)62-9
  • 19. Predicting drug activity in non-small cell lung cancer based on genetic lesions.
  • M.L. Sos, K. Michel, T. Zander, J. Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stückrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W.F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenführer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B.A. Weir, T.-H. Chen, H. Greulich, J. Barretina, G.I. Shapiro, L.A. Garraway, A.F. Gazdar, J.D. Minna, M. Meyerson*, K.-K. Wong* and R.K. Thomas*
  • J Clin Invest200919(6)1727-40